ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / MBOT / earnings
QTEX (31) LNSR (24) DAVI (47) SKIN (36) ⌘ Pro Terminal →

Microbot Medical Inc. (MBOT) Next Earnings Date & Expected ±12.5% Move

$1.09 -2.68% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.08

Microbot Medical Inc. (MBOT) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D- • RED ALERT Cap $75.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MBOT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MBOT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Microbot Medical Inc. (NASDAQ: MBOT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $1.09 (-2.68% 1D, market cap $75.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MBOT ranks #508 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MBOT compare to QTEX and LNSR in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), MBOT carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -15.8%. By comparison, QTEX (QTREX Quantum Ltd.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $73.9M) and LNSR (LENSAR Inc.) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $73.3M). Among the 5-stock peer group, MBOT leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MBOT?
▼

Per MBOT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000883975), Microbot Medical Inc. generated $0 in revenue, -$13.1M in net income, and -$13.1M in free cash flow against $81.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.08 (-0.67%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510041
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+
Cash (6)Whales (10)SEC (10)Macro (12)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-7.3% Base Target
$3 Bull$1 Base$1 Bear
📬 FREE MBOT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MBOT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (41/100 Composite)
🔍 WHY MBOT SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+12/20 pts (29% of score)

FRED Regime × Technicals: 8% of 52W Range • RSI-14 at 48.5 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+10/20 pts (24% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
33
Grade E$1.07-11.2% Next Q
Q2 (-2Q)
36
Grade E$0.95+2.1% Next Q
Q3 (-1Q)
38
Grade E$0.97+12.4% Next Q
Current
41
Grade D-$1.09-7.2% Hist 90D α
Trajectory: E (33) → D- (41)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MBOT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MBOT currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.25) and Max Pain ($1.14) forces dealer call-delta covering toward $3.00.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MBOT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MBOT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 41%NO 59%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.14 Expected Swing
$1.00 (-12.5%)Spot $1.09$1.23 (+12.5%)
MODEL EARNINGS SETUP GAUGE

MBOT Quantitative Pre-Earnings Setup: 41/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (41/100)Model Risk Weight (59/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$0-$13.1M-$13.1M52%
FY 20242024-12-31$0-$11.4M-$8.9M52%
FY 20232023-12-31$0-$10.7M-$8.5M52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MBOT)

  • ✓Walkthrough of MBOT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
MBOT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -47.85%▼ DESCENDING CHANNEL
2026-10-30O $1.11H $1.11L $1.04C $1.09VOL 1.33M
RES: $1.69SUP: $0.79SMA50: $1.25SMA200: $1.85
$2.66$2.19$1.72$1.25$0.78RES $1.69SUP $0.79$1.092026-04-302026-06-152026-07-312026-09-162026-10-30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MBOT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MBOT Butterfly Map → + Track MBOT →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MBOT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MBOT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MBOT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MBOT)

Health Care Rank #508 of 1016 ⚔️ QTEX vs MBOT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MBOT vs. QTEX, LNSR, DAVI, SKIN)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Microbot Medical Inc. (MBOT) ranks #508 by composite RQD confidence (41/100, grade D-) and #696 by equity capitalization ($75.2M). Within this direct 5-issuer industry benchmark cohort, MBOT leads on earnings valuation at N/A trailing P/E, while MBOT leads on capital efficiency and profitability with -15.8% ROIC and — gross margin. DAVI currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with MBOT at 41/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MBOT ACTIVE
Microbot Medical Inc.
D- 41/100 — — -15.8% -2.68% $75.2M Benchmark Subject
QTEX
QTREX Quantum Ltd.
E 31/100 — 0.7% -35.0% -7.58% $73.9M /qtex-vs-mbot →
LNSR
LENSAR Inc.
E 24/100 — 39.4% -35.0% -2.18% $73.3M /lnsr-vs-mbot →
DAVI
Davion Healthcare Plc
D 47/100 — — — -37.55% $67.3M /davi-vs-mbot →
SKIN
SkinHealth Systems Inc. (Class A)
D- 36/100 — 65.3% -26.9% -2.07% $66.0M /skin-vs-mbot →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000883975

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Microbot Medical Inc. (MBOT) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$13.1M, operating cash flow of -$13.0M, and free cash flow of -$13.1M (-48.1% YoY). On the balance sheet, MBOT closed FY2025 with $81.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $0 -$13.1M -$13.0M -$13.1M $81.5M —
FY2024 (FY) 2024-12-31 $0 -$11.4M -$8.8M -$8.9M $6.0M —
FY2023 (FY) 2023-12-31 $0 -$10.7M -$8.5M -$8.5M — —

3. MBOT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MBOT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Microbot Medical Inc. (NASDAQ: MBOT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $1.09 (-2.68% 1D, market cap $75.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MBOT ranks #508 in composite RQD confidence.

How does MBOT compare to QTEX and LNSR in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), MBOT carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -15.8%. By comparison, QTEX (QTREX Quantum Ltd.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $73.9M) and LNSR (LENSAR Inc.) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $73.3M). Among the 5-stock peer group, MBOT leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MBOT?

Per MBOT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000883975), Microbot Medical Inc. generated $0 in revenue, -$13.1M in net income, and -$13.1M in free cash flow against $81.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MBOT trading relative to its 50-day, 200-day, and 52-week technical levels?

MBOT last traded at $1.09 (-2.68% on volume of 1,334,965 shares), positioning the stock -12.80% below its 50-day simple moving average ($1.25) and -41.08% below its 200-day simple moving average ($1.85). Across its 52-week range of $0.93 to $2.86, MBOT sits at the 8.3% percentile with a 14-day RSI of 48.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.23).

MBOT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is MBOT's next earnings date?

Based on SEC filing cadence, Microbot Medical Inc. (MBOT)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is MBOT stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for MBOT, spanning a range between $1 and $1.23.

Direct Sub-Reports: MBOT RQD Cockpit MBOT 12M Forecast MBOT Earnings & Move MBOT Dividends & DRIP MBOT Insiders & 13F MBOT Whale Options MBOT Profit Sankey MBOT News & Why
ROARABLE RATING BRIEF • RQD 41/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

MBOT — Microbot Medical Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:45:25Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, MBOT scores 41 out of 100, grade D-, with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 6 / 20 (ROIC -15.8%; FCF yield -17.42%), Whale 13F Flow at 10 / 20 (institutional accumulation and options positioning), Insider Conviction at 3 / 20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 12 / 20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 10 / 20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5).

Read together, the lowest-scoring pillars point to weak cash generation and thin insider conviction as the main constraints. Negative ROIC and negative FCF yield indicate the business is not currently converting capital into returns, so any upside case depends on future operating change rather than present earnings power. The Forensic pillar's Piotroski F of 2/9 is a weak reading, though the Altman Z of 2.5 and a Debt/Equity of 0.5 suggest the balance sheet is not the sole driver of the low score. The Whale flow score is the strongest pillar, indicating some institutional interest, but it does not offset the weak fundamentals. Upside drivers would need to come from a shift in cash-flow trajectory; valuation tradeoffs are sharp given a $1.09 price against a $75.2M market capitalization with no earnings-based multiples available. Ripple effects are limited because no supply-chain links are recorded.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$0.0M$-14.7M$-13.1MN/A$-13.1M$3.9MN/A
FY 2024$0.0M$-11.6M$-11.4MN/A$-8.9M$3.1MN/A
FY 2023$0.0M$-9.9M$-10.7MN/A$-8.5MN/AN/A

Per the SEC financials, the company reported losses at both the operating and net levels in every period shown, with operating losses widening from $-9.9M to $-14.7M and FCF moving from $-8.5M to $-13.1M. Gross, operating, and net margins are each reported as 0%. Per the market data, ROIC is -15.8% and FCF yield is -17.42%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 2/9, and Debt/Equity is 0.5. Reported cash rose from $3.1M to $3.9M across FY 2024 to FY 2025.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the items are headline-level and carry a YELLOW light and MARKET WIRE impact label:

  • A Yahoo Finance Australia market-wire item on MBOT stock price, news, and history (1h ago).
  • An Investing.com item reporting that the H.C. Wainwright price target was maintained at $12 (3h ago).
  • A TradingView estimates page for MBOT (6h ago).
  • A Stock Titan item reporting that an Israeli distributor received exclusive rights to sell a robot for blood-vessel procedures (9h ago).
  • A Simply Wall St item on MBOT's cash burn rate (12h ago).
  • A GuruFocus item reporting that MBOT secured multiple new patents across key global markets (15h ago).

Risk watch items are the cash burn and negative FCF already reflected in the financials. The Butterfly graph records no proprietary signals.

Open Questions

  • What is the revenue status given $0.0M reported across all three periods, and what commercial milestones underlie the distributor and patent headlines?
  • What are the EPS and valuation multiples (P/E, EV/EBITDA), which are unreported?
  • What is the debt position, since debt is reported as N/A in each period despite a Debt/Equity of 0.5?
  • What is the cash runway implied by $3.9M cash against FY 2025 FCF of $-13.1M, and what financing plans exist?
  • Who are the institutional holders, insiders, and analysts covering the stock, given the holders and analyst sections are empty?

MBOT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Microbot Medical Inc. (MBOT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MBOT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MBOT Bull vs. Bear Conversation Board — What's Your Call at $1.09?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MBOT 🐻 67% BEARISH CONVICTION
1. Pick Your Side on MBOT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.96 (-11.9%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is MBOT (D- • RQD 41/100) a Buy at $1.09?

Welcome to the MBOT (Microbot Medical Inc.) Roar Pit. Current RQD Composite is 41/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.84 (-22.9%)
Spot @ $1.09

Pump the brakes on MBOT — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on MBOT, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Microbot Medical Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.32 (+21.1%)
Spot @ $1.09

MBOT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on MBOT, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $1.09 (52-wk range $0.93 - $2.86), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%